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miR146a, miR195 etc. (Feng et al., 2011; McArthur et al., 2011;
Mortuza et al., 2014). However, in most of these publications, inves-
tigators used a particular miRNA to target a single mRNA. In this pub-
lication, Wang et al. used miR15a to demonstrate that it can be
helpful in preventingmultiple important biologic processes of signif-
icance in diabetic retinopathy, such as increased permeability andmiR15a
Endothelial cells
Diabetic retinopathyIn this issue of EBioMedicine, Wang and colleagues have demonstrated
an important role played by miR15 in diabetic retinopathy (Wang et al.,
2016). Using a large number of tools and state of the art technology
they showed that in diabetes, miR-15a is reduced both in the bone mar-
row cells and in the retina. Inhibition of miR-15a upregulated acid
sphingomyelinase (ASM), a pro-inﬂammatorymolecule and vascular en-
dothelial growth factor A, an angiogenic molecule expression in the reti-
nal pigment epithelial cells and endothelial cells. Furthermore,
migration and retinal vascular repair function was impaired in miR-15a
inhibitor-treated circulating angiogenic cells. They further expanded the
study to the animal model where they used mice with miR-15a overex-
pression using Tie-2 promoter. Diabetes induced increased retinal perme-
ability was prevented in these mice. However, such miR-15a
overexpression, although reduced ASM and VEGF-A expressions, didn't
abolish it completely.
MicroRNAs are increasingly being recognized as molecules with
signiﬁcant modulatory action, inmultiple if not all biologic processes
(Ghildiyal and Zamore, 2009). Hence, it is highly likely that they are
also involved in disease processes and diabetic retinopathy is no ex-
ception. Here, this group with longstanding interest and expertise in
diabetic retinopathy research demonstrated that miR15 is a poten-
tial drug target for the treatment of diabetic retinopathy (add
Wang et al. ref.). In keeping with this research, previous studies
from several groups including these investigators have demonstrat-
ed alterations of multiple microRNAs in chronic diabetic complica-m.2016.08.013.
Western University, Rm 4033,
en access article under the CC BY-NCtions including diabetic retinopathy. The list include miR200b,
angiogenesis (mediated by VEGFA) and inﬂammatory cytokine pro-
duction (mediated by ASM) (Penn et al., 2008; Yu et al., 2015). It is
of further interest to note that bone marrow derived circulating an-
giogenic cells (CACs), which normally repairs endothelial injury,
are unable to do such repair in diabetes (Kern and Grant, 2013).
However miR15a overexpression also corrected these derangements
as demonstrated here. Interestingly, although miR15a directly tar-
gets VEGFA, its acts on the inﬂammatory mediators through ASM ac-
tivation and ceramide production, which allowed it to regulate
multiple pro-inﬂammatory transcripts. In addition, as noted,
miR15a also regulates FGF-2. What role FGF-2 played in the context
of current pathologies remains to be explored.
There are additional important noteworthy points. Although both reti-
nal pigment epithelial cells (RPE) and endothelial cells showed glucose in-
duced reduction of miR15a and associated alteration, overexpression of
miR15a in the endothelial cells (as Tie2 is not expressed in the RPE)
prevented diabetes induced changes in the retina, further establishing
the notion that retinal endothelial cells are the primary target of tissue
damage in diabetes (Khan and Chakrabarti, 2007). However, Tie-2 ex-
pressing circulating angiogenic cells (aka endothelial progenitor cells)
also contributed to miR15a’s preventive effects on the retinal damage in
diabetes.
One of the main challenges in the micro RNAs based therapy is that
one miRNA has multiple targets and one transcript is regulated post
transcriptionally not only by multiple miRNAs, but also by other epige-
netic phenomena including other non-coding RNAs, methylation etc.
(Ghildiyal and Zamore, 2009; Ruiz et al., 2015). Hence, further investi-
gations related to miR15a's biogenesis and regulations in the context
of diabetes are warranted.
In some instances, where alterations of multiple molecules, con-
trolled by one miRNA lead to pathogenesis of a disease, speciﬁc
miRNA may lend itself to be a potential therapeutic target as shown in
this paper. However, a large number of other transcripts are also regu-
lated by miR15a (www.targetscan.org). Hence, other off-target actions
may also potentially act as disease modiﬁers. Furthermore, long term-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
14 S. Chakrabarti / EBioMedicine 11 (2016) 13–14effects of miR15a manipulation in any disease process as well as on
other organs are not clear. Hence, long-term studies in larger animal
models are needed to broaden our understanding of microRNA based
therapy for a chronic disease such as diabetic retinopathy.
Nevertheless the current research is an important step towards de-
veloping novel therapeutic approach for the treatment of diabetic reti-
nopathy. From a mechanistic standpoint, it is important to understand
these novel molecular regulations aimed towards the development of
RNA based therapy for this disease.
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